MedTrace Logo

DPP4 Inhibitor on Glycemic Variability

NCT04654676 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-12-19

No results posted yet for this study

Summary

The investigators conducted a prospective study in patients with T2DM on twice daily MHI with or without metformin therapy. Blinded continuous glucose monitoring was performed at baseline and following 6 weeks of Vildagliptin therapy.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Vildagliptin

Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin

Sponsors & Collaborators

  • Sarawak General Hospital

    collaborator OTHER

  • University Malaysia Sarawak

    lead OTHER

Principal Investigators

  • Florence Tan · Sarawak General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04654676 on ClinicalTrials.gov